TEK is altered in 3.12% of nasal cavity and paranasal sinus carcinoma patients [3].

TEK is an inclusion criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TEK status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

TEK is altered in 6.67% of nasopharyngeal carcinoma patients [3].

TEK is an inclusion criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TEK status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

TEK is altered in 1.4% of oropharyngeal carcinoma patients [3].

TEK is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TEK status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

TEK is altered in 1.95% of urothelial carcinoma patients [3].

TEK is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TEK status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

TEK is altered in 1.78% of gastric carcinoma patients [3].

TEK is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TEK status and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

TEK is altered in 1.73% of malignant solid tumor patients [3].

TEK is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains TEK status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [4].

TEK is altered in 1.45% of non-small cell lung carcinoma patients [3].

TEK is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TEK status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

TEK is altered in 1.83% of gastrointestinal stromal tumor patients [3].

TEK is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains TEK status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [4].

TEK is altered in 1.39% of pancreatic carcinoma patients [3].

TEK is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TEK status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

TEK is altered in 1.97% of adenocarcinoma of the gastroesophageal junction patients [3].

TEK is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains TEK status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [4].

TEK is altered in 0.72% of prostate carcinoma patients [3].

TEK is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TEK status and prostate carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

TEK is altered in 0.57% of hepatobiliary neoplasm patients [3].

TEK is an inclusion criterion in 1 clinical trial for hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TEK status and hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

TEK is altered in 0.57% of malignant hepatobiliary neoplasm patients [3].

TEK is an inclusion criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TEK status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

TEK is altered in 1.25% of malignant salivary gland neoplasm patients [3].

TEK is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TEK status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

TEK is altered in 1.48% of lip and oral cavity carcinoma patients [3].

TEK is an inclusion criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TEK status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

TEK is altered in 1.63% of esophageal carcinoma patients [3].

TEK is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TEK status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

TEK is an inclusion criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TEK status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].